Peerview Neuroscience & Psychiatry Cme/cne/cpe Audio Podcast

Informações:

Synopsis

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Episodes

  • Jerome A. Barakos, MD / Tammie L.S. Benzinger, MD, PhD - Improving the Recognition and Management of Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer’s Disease Treatment: Practical Tools and Strategies for Radiology and Neuroradiology Specialists

    11/03/2024 Duration: 01h08min

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MCV865. CME/AAPA credit will be available until March 14, 2025.Improving the Recognition and Management of Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer’s Disease Treatment: Practical Tools & Strategies for Radiology & Neuroradiology Specialists In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure Po

  • Manmeet S. Ahluwalia, MD, MBA, FASCO - Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy

    12/01/2024 Duration: 16min

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigate

  • James F. Howard Jr., MD - FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

    01/12/2023 Duration: 01h04min

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have be

  • Claudia A. Chiriboga, MD, MPH, FAAN - Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood

    24/11/2023 Duration: 01h01min

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CRG865. CME/AAPA credit will be available until November 5, 2024.Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commen

  • Alan K. Percy, MD - From Early Recognition to Age- and Stage-Appropriate Care: Navigating a New Era in Rett Syndrome Management

    24/11/2023 Duration: 28min

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NQQ865. CME credit will be available until November 9, 2024.From Early Recognition to Age- and Stage-Appropriate Care: Navigating a New Era in Rett Syndrome Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencemen

  • Eric Marsh, MD, PhD - Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management

    24/11/2023 Duration: 51min

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UDJ865. CME credit will be available until November 20, 2024.Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the comme

  • James D. Berry, MD, MPH - Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options

    24/11/2023 Duration: 01h50s

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant

  • Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP / Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE - Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Consideration

    31/10/2023 Duration: 57min

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865. NCPD/CE/AAPA credit will be available until November 11, 2024.Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered CareOptimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence.Recent research has focused on novel pathways involved in the etiolo

  • Jeffrey L. Neul, MD, PhD - The Changing Future for Patients With Rett Syndrome and Their Families: Early Diagnosis and New and Emerging Therapies to Reduce the Burdens of Disease

    19/10/2023 Duration: 55min

    Go online to PeerView.com/VWR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Due to the rarity of Rett syndrome and overlapping symptoms with other, more common neurodevelopmental disorders, diagnosis is challenging and often missed or delayed. With one Rett-targeted therapy recently approved and others in development, clinicians now have the opportunity to offer not merely symptom management but potential clinical improvement. This PeerView case-based activity is designed to improve your ability to recognize, diagnose, and treat patients with Rett syndrome. Each session features a realistic case discussion with expert faculty panelists sharing the evidence that supports clinical decisions for timely diagnosis and early initiation of multidisciplinary management and targeted therapy as appropriate. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in patients

  • Michael Levy, MD, PhD - Test Your Knowledge: Are You Missing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease (MOGAD)?

    29/08/2023 Duration: 35min

    Go online to PeerView.com/CTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) was identified as a distinct demyelinating disease entity only recently. Prior to this characterization of MOGAD, many patients were considered to have a variant of MS, NMOSD, or other neurologic condition. Now an international panel of experts has proposed diagnostic criteria that, when validated, promise to improve MOGAD diagnostic accuracy and confidence. This is particularly important, given that several clinical trials are investigating potential treatments for MOGAD. This unique PeerView activity will use problem-based educational interventions to expose learners to the science and clinical experience behind accurate diagnosis and best practices in management of MOGAD. You will be able to employ optimal clinical decision-making for your patients with MOGAD that is based on the latest evidence, best pr

  • Stephen P. Salloway, MD, MS - Case by Case: Actioning Patient-Centered Strategies for Risk Assessment, Diagnosis, and Management of Amyloid-Related Imaging Abnormalities (ARIA)

    24/08/2023 Duration: 01h03min

    Go online to PeerView.com/QVT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age and increasing as the population ages. After almost two decades without a new AD treatment, recent advances in disease-modifying therapies—including the accelerated FDA approval of two amyloid-targeting therapies (ATTs) and a third in late-stage development—have introduced the possibility of slowed disease progression and improved patient outcomes. Furthermore, significant advances have been made in identifying and testing biomarkers for AD that may aid in early diagnosis, proper treatment selection, and assessment of therapeutic response. The latter is increasingly important given the need to monitor for amyloid-related imaging abnormalities (ARIA) in patients being prescribed ATTs for mild cognitive impairment due to AD or mild AD dementia. With the rapid deve

  • Philip Harvey, PhD - Visualizing a New Horizon: Emerging Advances in the Treatment of Cognitive Impairment Associated With Schizophrenia

    07/08/2023 Duration: 31min

    Go online to PeerView.com/FMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore recent advances in the management of cognitive impairment associated with schizophrenia (CIAS) and learn how to implement current and emerging treatment strategies into individualized care plans to improve your patients’ outcomes and quality of life. Upon completion of this activity, participants should be better able to: Summarize the burdens of cognitive impairment in patients with schizophrenia and its impact on patient outcomes and quality of life; Describe the pathophysiology of CIAS, emphasizing the difference between negative symptoms and cognitive impairment; and Implement current and emerging treatment strategies for CIAS, taking into account the latest evidence and patient treatment goals, preferences, and unmet needs.

  • Ilya M. Nasrallah, MD, PhD - Navigating the New Era of Molecularly Defined Care in Alzheimer’s Disease: Applying Nuclear Medicine to Quantify Neuropathology and Improve Diagnostic Accuracy in the Earliest Stages of the AD Continuum

    28/07/2023 Duration: 54min

    Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances h

  • Jiwon Oh, MD, PhD, FRCPC - New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

    05/07/2023 Duration: 46min

    Go online to PeerView.com/JHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent research and improved understanding of the pathogenesis of multiple sclerosis (MS) has led to the development of multiple biomarkers and imaging modalities that can improve clinicians’ ability to individualize therapy through more effective monitoring of disease progression and treatment response. The promise of eventually arriving at data-driven personalized care—coupled with the number of available and emerging therapies for MS treatment—makes it more important than ever that clinicians remain up-to-date on advances in biomarkers and imaging approaches, as well as shared decision-making strategies. In this activity, based on a recent live symposium, MS experts cover the latest data on these new and emerging biomarkers for MS management. Using examples from their own practice, the panelists also discuss ways to incorporate these biomarker findings into individualized tre

  • Amit Bar-Or, MD, FRCPC - Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

    05/07/2023 Duration: 43min

    Go online to PeerView.com/YAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials. As such, clinicians must remain up to date with the latest data on the rationale for their use and trial findings on the efficacy, safety, and tolerability of this promising line of treatment. At a recent PeerView live event, MS experts shared relevant stories from their practice to highlight the rationale for the use of BTK inh

  • Jessica Ailani, MD, FAHS, FAAN, FANA - Breakthrough Therapies for the Prevention and Acute Treatment of Migraine: Addressing Unmet Needs in the Primary Care Setting

    27/06/2023 Duration: 28min

    Go online to PeerView.com/MWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, Dr. Jessica Ailani reviews the latest data on therapies for acute and preventive management of migraine, with a focus on personalized treatment. A patient interview and 3D animation are also part of this engaging video program. Upon completion of this activity, participants should be better able to: Apply safety and efficacy data related to new acute migraine therapies in clinical decision-making, taking into account patient-reported outcomes; Employ evidence-based prevention strategies for patients with migraine; and Implement individualized treatment plans for patients with migraine.

  • Vera Bril, BSc, FRCPC, MD - Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals

    01/06/2023 Duration: 57min

    Go online to PeerView.com/EZC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An international panel of experts discusses the data on clinical outcomes, safety, and efficacy of new and emerging therapies for the treatment of myasthenia gravis. The interdisciplinary discussion focuses on FcRn modulation and personalized treatment approaches, and includes an interview with a patient who discusses her life and treatment journey with myasthenia gravis. Upon completion of this activity, participants should be better able to: Integrate new and emerging gMG-targeted therapies into treatment plans as appropriate, based on an understanding of the data on clinical outcomes, safety, and effects on quality of life; Develop a management strategy that incorporates the patient’s perspective in identifying treatment goals and choices; and Implement a safe, individualized administration protocol for the management of gMG that responds to clinical and patient-reported outc

  • Daniel S. Reich, MD, PhD - Targeting BTK: The Latest Data on the Evolving Treatment Landscape for Patients With MS

    01/06/2023 Duration: 32min

    Go online to PeerView.com/TFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this video, an expert reviews new data on the potential role of BTK inhibitors in the treatment of patients with multiple sclerosis presented at the American Academy of Neurology 2023 annual meeting. Learn how BTK inhibitors compare with anti-CD20 monoclonal antibodies and why this emerging class of DMTs may present a safe, effective, and highly selective treatment option with a low risk of opportunistic infections and possibly the ability to cross the blood–brain barrier, with results that may include a meaningful effect on proinflammatory cells in the CNS and the potential to prevent disability progression. Upon completion of this activity, participants should be better able to: Discuss the mechanism of action of Bruton tyrosine kinase (BTK) inhibitors in the targeted treatment of MS; Assess the current evidence regarding the efficacy, safety, and tolerability of BTK inhibi

  • Anna Chodos, MD, MPH - Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

    01/06/2023 Duration: 58min

    Go online to PeerView.com/XUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process. Upon completion of this activity, part

  • Robert C. Green, MD, MPH - Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients?

    06/04/2023 Duration: 01h05min

    Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer’s disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the

page 1 from 3